Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis

Summary

The purpose of this Phase 2 study is to evaluate the efficacy and safety of momelotinib (MMB) in combination with luspatercept (LUSPA) in participants with transfusion dependence (TD) primary myelofibrosis (PMF) or Post-polycythemia vera (PV)/ essential thrombocythemia (ET) myelofibrosis (MF) who are either janus kinase (JAK) inhibitor (JAKi) naïve or experienced.

Timeline

Start

2025-02-28

Primary completion

2027-03-19

Completion

2028-03-17

Drugs

Indications